in

China’s central bank injects cash via new outright reverse repos in October

The People’s Bank of China (PBOC) said the repo operations aimed to “keep banking system liquidity reasonably ample”. The tenor of the repos for the month was six months.

The new tool, announced on Monday, which supports credit flow in the banking system ahead of the expiration of trillions of yuan in loans at the end of the year, also offers the regulator additional sources of bonds that it can sell in the future.

“While the central bank’s current holdings of government bonds are sufficient for existing operations, it needs to establish additional channels for bond holdings. This will lay the groundwork for future bond sales and swap facility operations,” analysts at China Securities said in a note.

Unlike pledged repos that the PBOC typically uses in regulator reverse repo operations, the title of the collateral in an outright repo transaction is sold to the buyer. That means the PBOC will have more flexibility to meet liquidity needs by selling the bonds it holds.

Separately, the central bank said it had purchased a net 200 billion yuan of government bonds in open market operations in October, according to official statements. The bank did not specify whether it bought or sold short-term or long-dated bonds as it did in August.

Until late September, China’s bond market had seen a prolonged record-breaking rally as banks and investors sought safer assets in a flailing economy. The central bank warned market participants for weeks about the inflated prices of bonds and sold long-dated bonds in August to cool a feverish market.

Ten-year and 30-year sovereign bond yields were down 1 basis points (bps) and 3 bps, respectively.

Traders and investors are eagerly awaiting next week’s key leadership meeting, with any fiscal stimulus falling short of expectations likely to drive yields lower.

($1 = 7.1180 Chinese yuan renminbi)


Source: Economy - investing.com

Maersk chief predicts intensifying trade tensions after US elections

Eurozone inflation rises to 2% in October